12,372 trials
Von Willebrand Disease
Primary: Overall Hemostatic Efficacy as Assessed by the Investigator (Hemophilia Physician) — 11; 4; 7; 0 Participants
Hepatitis C Virus
Primary: Percentage of Participants in Arms A, B and C With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 96.6; 100.0; 93.4 percentage of participants
Urothelial Cancer
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - All Participants — 3.3; 2.1 Months — p=0.41648
Chronic Hepatitis C · Cirrhosis · Hepatitis C Virus
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 93.9 percentage of participants
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (16 Hours Post-dose) — 1.91; 2.00; 1.65; 2.48 units on a scale
Post-surgical Pain Following Extraction of Molar Teeth
Primary: Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 8 Hours Post-dose (SPID11 [0-8]) — 4.1; 34.3; 28.9; 19.4 units on a scale…
Anesthesia
Primary: Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic. — 46; 16 Participants
Anesthesia
Primary: Number of Participants Who Completed the Study Dental Procedure After Without Need for Rescue by Injection of Local Anesthetic. — 84.1; 27.3; 27.3 percentage of patients
Analgesia
Primary: Percentage of Participants Who Correctly Select to Use or Correctly De-select Not to Use Ibuprofen 600 Milligram (mg) Immediate Release (IR) or Extended Release (ER)…
Neonatal Abstinence Syndrome
Primary: Fetal Heart Rate — 145.7; 143.3; 138.6; 136.3 beats per minute — p=0.001
Hepatitis B
Primary: Percentage of Seroresponders Before and After the Challenge Vaccination — 45.5; 58.8; 85.2; 88.3 Percentage of participants
Andropause
Primary: Sexual Function Trial - Change in Psychosexual Daily Questionnaire Question 4 (PDQ-Q4) From Baseline to Month 12 — 1.4; 1.4; 0.6; 0.1 units on the PDQ-Q4 scale — p=<0.001
Acne
Primary: The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements — 85; 73 count of participants
Otitis Media With Effusion in Children · Otitis Media Recurrent
Primary: Percentage of Subjects With Sustained Clinical Cure at Day 8 — 77.1; 75.5; 65.3 percentage of participants
Acute Migraine
Primary: Number of Participants With Treatment Emergent Adverse Events — 120 Participants